KALA Insider Trading
Insider Ownership Percentage: 8.32%
Insider Buying (Last 12 Months): $1,999,999.96
Insider Selling (Last 12 Months): $255,095.17
KALA BIO Share Price & Price History
Current Price: $6.05
Price Change: ▼ Price Decrease of -0.27 (-4.27%)
As of 03/28/2025 05:00 PM ET
KALA BIO Insider Trading History
KALA BIO Institutional Trading History
Data available starting January 2016
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Read More on KALA BIO
Volume
36,536 shs
Average Volume
85,255 shs
Market Capitalization
$36.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of KALA BIO?
Who are the major institutional investors of KALA BIO?
KALA BIO's top institutional shareholders include:
- Baker BROS. Advisors LP — 19.74%
- SR One Capital Management LP — 9.83%
- Silverarc Capital Management LLC — 3.79%
- ADAR1 Capital Management LLC — 3.62%
- OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC — 2.94%
- Millennium Management LLC — 2.23%
Learn More about top institutional investors of KALA BIO stock.
Which institutional investors are selling KALA BIO stock?
Within the previous quarter, KALA stock was sold by these institutional investors:
- ADAR1 Capital Management LLC
- Millennium Management LLC
- Two Sigma Investments LP
In the previous year, company insiders that have sold KALA BIO company stock include:
- Bros Advisors Lp Baker (Major Shareholder)
- Mark T Iwicki (CEO)
- Todd Bazemore (Insider)
- Mary Reumuth (CFO)
Learn More investors selling KALA BIO stock.
Which institutional investors are buying KALA BIO stock?
Within the previous quarter, KALA stock was bought by institutional investors including:
- Baker BROS. Advisors LP
- Silverarc Capital Management LLC
- SR One Capital Management LP
- AIGH Capital Management LLC
- OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC
- Geode Capital Management LLC